Back to School: How biopharma can reboot drug development. Access exclusive analysis here

XL184: Interim Phase I data

Exelixis Inc. (EXEL), South San Francisco, Calif.
Product: XL184
Business: Cancer
Molecular target: Vascular

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE